Leonard Mazur
From FDA Approval to Revenue: Launching a Cancer Therapy
Leonard Mazur
Chairman and CEO, Citius Pharmaceuticals

From FDA Approval to Revenue: Launching a Cancer Therapy

With Leonard Mazur
Listen to the podcast:
Apple Podcasts logoListen to podcasts on SoundCloudListen to podcasts on SpotifyWatch podcast on YouTubeiHeart Podcast Interview logoPodbean podcast platform logo
TuneIn podcast platform logo

Getting a cancer therapy approved is a major milestone. Getting it into the hands of the physicians and patients who need it is a different challenge altogether. In this episode of the Healthcare Success Podcast, I speak with Leonard Mazur, Chairman and CEO of Citius Pharmaceuticals, about what happens when a biotech company moves from raising capital to creating revenue.

Leonard has spent more than 50 years in pharmaceuticals, building businesses, buying and repositioning drug assets, and learning to take calculated risks. His entrepreneurial career provides the backdrop for Citius’s work with LYMPHIR, a therapy for cutaneous T-cell lymphoma (CTCL), a rare cancer. We discuss how the company acquired the asset, navigated the regulatory process, and prepared for commercialization.

One important distinction Leonard makes is that FDA approval isn’t the finish line. After the drug received approval in 2024, difficult capital-market conditions delayed a full commercial rollout. Citius used that time to prepare its distribution, reimbursement, patient-support and field-sales infrastructure, then launched in stages in 2026. The company also shifted from a predominantly technical organization to one that needed experienced commercial leadership and a coordinated sales operation.

For healthcare marketers, the rare-disease strategy is particularly instructive. Rather than reaching a broad population, Citius uses claims data to identify physicians treating CTCL patients and understand their affiliations with academic and community centers. Leonard also explains the importance of patient advocacy organizations, key opinion leaders, medical science liaisons and community treatment access. Each element serves a different role, but they need to work together.

We also discuss the potential for future research beyond the drug’s approved indication, including investigator-led studies in combination with other cancer therapies. Leonard is careful to distinguish promising early findings from what further clinical data still needs to establish.

Throughout the conversation, Leonard returns to a lesson that applies far beyond pharmaceuticals: relationships matter. Experienced partners can help a small company execute complex work, while longstanding connections with colleagues, physicians and advisers can shorten the learning curve. His story is a useful reminder that a successful launch requires more than a promising product. It requires capital, operational discipline, the right team and the ability to make those pieces work together.

Why Listen?

In this episode, listeners will learn:

  • Why FDA approval is only one milestone in the commercialization of a new therapy.
  • How a biotech company changes when its priority shifts from fundraising to revenue generation.
  • How claims data, physician targeting and patient advocacy shape rare-disease marketing.
  • Why specialized commercial partners and experienced hires matter for smaller pharmaceutical companies.
  • How relationships and calculated risk-taking influence long-term entrepreneurial success.

Key Insights and Takeaways

  1. Approval and launch require different capabilities. Regulatory, clinical and manufacturing expertise must be complemented by marketing, sales, distribution and reimbursement operations.
  2. Capital availability can determine launch timing. Citius received approval in 2024, but Leonard says market conditions delayed its full commercial rollout until 2026.
  3. A rare-disease sales strategy can be highly focused. Claims data helps identify CTCL treaters and their affiliated academic and community centers instead of relying on a broad field force.
  4. Patient access is an operational responsibility. The company describes using a patient hub and reimbursement support to reduce treatment-related friction.

5. External partners can provide infrastructure without requiring a small biotech to build everything internally. Leonard describes working with Eversana on commercialization services.

6. Scientific credibility depends on sustained relationships. Citius works with key opinion leaders, a scientific advisory board and medical science liaisons alongside its commercial team.

7. Future indications remain a research opportunity, not an established outcome. Leonard describes investigator-led combination studies while emphasizing the need for more clinical data.

8. Leadership and relationships reinforce execution. Leonard credits experienced teams, transparency and longstanding professional connections as central to building a company.

“If you’re not living on the edge, then you’re taking up too much space.”
Leonard Mazur

Leonard Mazur

Chairman and CEO, Citius Pharmaceuticals

Subscribe for More

Don’t miss future insights—subscribe to our blog and join us on LinkedIn: Stewart Gandolf and Healthcare Success.

Note: The following AI-generated transcript is provided as an additional resource for those who prefer not to listen to the podcast recording. It has been lightly edited and reviewed for readability and accuracy.

Like Our Content?
Sign Up for Our Blog, Podcasts, Webinars, and eBooks Here.

Ready to explore a partnership?
© 2026 Healthcare Success, LLC. All rights RESERVED.